Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(50%)
Terminated
1(50%)

Phase Distribution

Ph phase_2
1
50%
Ph phase_1
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

terminated150%
recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
recruitingphase_2

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

NCT06651593
terminatedphase_1

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

NCT04717375

Clinical Trials (2)

Showing 2 of 2 trials
NCT06651593Phase 2

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

Recruiting
NCT04717375Phase 1

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2